Angiotensin Converting Enzyme (ACE) Inhibition and Peripheral Arterial Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Leg pain caused by peripheral arterial disease (PAD) can severely impede walking ability. Our preliminary findings indicate that the drug ramipril is much more effective in improving walking ability than current therapies. To be accepted as a new treatment for PAD these findings require validation in a much larger clinical trial.We propose to examine the effects of ramipril therapy for 6 months in a randomized, controlled trial of patients with PAD. If positive, this study will identify ramipril as a potential new therapy for PAD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

NCT00005928

Atherosclerosis Coronary Disease Vasculitis

COMPLETED PHASE2

The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

NCT00168467

Peripheral Arterial Disease

COMPLETED PHASE4

Personalizing Aspirin Therapy in Peripheral Arterial Disease Patients

NCT04269863

Peripheral Arterial Disease

UNKNOWN NA

Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction

NCT02525081

Microvascular Angina

COMPLETED PHASE4

Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization

NCT05308030

Peripheral Arterial Disease

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This proposal extends our novel finding that the angiotensin-converting enzyme (ACE) inhibitor, ramipril markedly improves walking ability in patients with peripheral arterial disease (PAD), by conducting a larger clinical trial including a broader cross-section of PAD patients.

Hypothesis:

That ramipril therapy for 24 weeks will result in clinically significant increases in both pain-free and maximum walking time and improve quality of life in patients with PAD.

Background Synopsis:

Peripheral arterial disease is a common disorder, with 12% of adults over 50 having an ankle-brachial index (ABI) diagnostic of PAD (\<0.9). Approximately one third of these patients experience intermittent claudication during walking, limiting the ability of these older individuals to participate in normal activities. The aim of PAD treatment is to improve walking distance and quality of life in those with intermittent claudication, and to decrease long term cardiovascular morbidity and mortality. However, the range of medical treatments to improve walking distance in these patients is limited. Our pilot study demonstrates that treatment of PAD patients, with infra-inguinal disease and without diabetes with ramipril for 24 weeks, markedly improves waking ability. Relative to placebo, ramipril increased mean treadmill-assessed pain-free waking time by 227s (160%, p\<0.001) and mean maximum walking time by 451s (240%, p\<0.001). Assuming a constant speed of 0.89 m/s (3.2 km/hr), this corresponds to a clinically significant increase in walking distance of 401m (95% CI 330m to 480m) which would impact appreciably on daily functional capacity. The magnitude of this effect is significantly greater than that reported for conventional medical therapies and provides worthwhile clinical benefit.

Research Plan Synopsis:

The dramatic findings of our pilot study clearly warrant verification in a larger clinical trial including diabetic patients and those with aorto-iliac disease as well as infra-inguinal disease. The current proposal is to expand our pilot study into a large trial with broad inclusion criteria. We propose to include patients with diabetes mellitus not currently medicated with ACE inhibitors. 264 PAD patients will be randomised to either ramipril (10mg once daily) or matching placebo for 24 weeks in a randomised, double-blind placebo controlled trial. All patients will undergo a treadmill exercise test to determine pain free and maximum walking times, ABI measurements and Duplex scanning to determine stenosis severity, both at baseline and following 6 months of ramipril therapy. Functional capacity in a daily life setting, will be assessed using standardised questionnaires (Walking Impairment Questionnaire and Quality of Life Questionnaire).

Outcomes and Significance:

If positive this trial will validate our pilot findings that the ACE inhibitor ramipril is an efficacious new therapy for the treatment of patients with claudication resulting from PAD. Given the escalating prevalence of PAD, this work has the potential for widespread impact.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ramipril or matching placebo

10 mg Ramipril or matching placebo once daily for 6 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ramace

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ankle brachial index of \<0.9 in at least one leg
* History of intermittent claudication (unilateral or bilateral)
* A stable medication regimen for at least 6 months

Exclusion Criteria

* Limiting coronary artery disease
* Renal failure (serum creatinine \> 0.20 mmol/L)
* Current treatment or treatment within the previous 6 months with ACE inhibitors or angiotensin II receptor antagonists

Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No